Market Research Logo

Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2015

Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2015’, provides an overview of the Metastatic Renal Cell Carcinoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Renal Cell Carcinoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Metastatic Renal Cell Carcinoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Metastatic Renal Cell Carcinoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Metastatic Renal Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Metastatic Renal Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Metastatic Renal Cell Carcinoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Metastatic Renal Cell Carcinoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Metastatic Renal Cell Carcinoma Overview
Therapeutics Development
Pipeline Products for Metastatic Renal Cell Carcinoma - Overview
Pipeline Products for Metastatic Renal Cell Carcinoma - Comparative Analysis
Metastatic Renal Cell Carcinoma - Therapeutics under Development by Companies
Metastatic Renal Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes
Metastatic Renal Cell Carcinoma - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Metastatic Renal Cell Carcinoma - Products under Development by Companies
Metastatic Renal Cell Carcinoma - Products under Investigation by Universities/Institutes
Metastatic Renal Cell Carcinoma - Companies Involved in Therapeutics Development
Acceleron Pharma, Inc.
Amgen Inc.
Angiogene Pharmaceuticals Limited
Argos Therapeutics, Inc.
Astellas Pharma Inc.
Bayer AG
Beta Pharma, Inc.
Bionomics Limited
Cellceutix Corporation
Celldex Therapeutics, Inc.
Cerulean Pharma, Inc.
Dr. Reddy's Laboratories Limited
EirGenix Inc.
Eisai Co., Ltd.
Eli Lilly and Company
Epirus Biopharmaceuticals, Inc.
Exelixis, Inc.
Genor BioPharma Co., Ltd.
GlaxoSmithKline Plc
Hetero Drugs Limited
Hospira, Inc.
immatics biotechnologies GmbH
Immune Design Corp.
Immunicum AB
Inbiopro Solutions Pvt. Ltd.
Mabion SA
Merck & Co., Inc.
NewLink Genetics Corporation
Novartis AG
Oncobiologics, Inc.
Ono Pharmaceutical Co., Ltd.
Panacea Biotec Limited
Peloton Therapeutics, Inc.
Prima BioMed Ltd.
Rexahn Pharmaceuticals, Inc.
Seattle Genetics, Inc.
Syndax Pharmaceuticals, Inc.
TVAX Biomedical, Inc.
Metastatic Renal Cell Carcinoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AGS-16C3F - Drug Profile
aldesleukin - Drug Profile
bevacizumab biosimilar - Drug Profile
bevacizumab biosimilar - Drug Profile
bevacizumab biosimilar - Drug Profile
bevacizumab biosimilar - Drug Profile
bevacizumab biosimilar - Drug Profile
bevacizumab biosimilar - Drug Profile
bevacizumab biosimilar - Drug Profile
bevacizumab biosimilar - Drug Profile
bevacizumab biosimilar - Drug Profile
bevacizumab biosimilar - Drug Profile
bevacizumab biosimilar - Drug Profile
BNC-105 - Drug Profile
BPI-3119 - Drug Profile
cabozantinib s-malate - Drug Profile
capmatinib - Drug Profile
Cell Therapy for Metastatic Renal Cell Carcinoma - Drug Profile
CRLX-101 - Drug Profile
dalantercept - Drug Profile
Dendritic Cell Therapy for Metastatic Renal Cell Carcinoma and Melanoma - Drug Profile
entinostat - Drug Profile
everolimus - Drug Profile
G-305 - Drug Profile
IBPM-002BZ - Drug Profile
IMA-901 - Drug Profile
IMP-321 - Drug Profile
Intuvax - Drug Profile
KM-3174 - Drug Profile
lenvatinib - Drug Profile
LY-2510924 - Drug Profile
Monoclonal Antibody Conjugated to Target Cells Expressing Antigen G250 for Renal Cell Carcinoma - Drug Profile
nivolumab - Drug Profile
Orellanine - Drug Profile
panobinostat - Drug Profile
pazopanib hydrochloride + pembrolizumab - Drug Profile
pembrolizumab - Drug Profile
PT-2385 - Drug Profile
radium Ra 223 dichloride - Drug Profile
Recombinant Protein for Oncology - Drug Profile
rilotumumab - Drug Profile
rocapuldencel-t - Drug Profile
RX-0201 - Drug Profile
SGN-CD70A - Drug Profile
trebananib - Drug Profile
TVI-Kidney-1 - Drug Profile
varlilumab - Drug Profile
ZD-6126 - Drug Profile
Metastatic Renal Cell Carcinoma - Recent Pipeline Updates
Metastatic Renal Cell Carcinoma - Dormant Projects
Metastatic Renal Cell Carcinoma - Discontinued Products
Metastatic Renal Cell Carcinoma - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Metastatic Renal Cell Carcinoma, H2 2015
Number of Products under Development for Metastatic Renal Cell Carcinoma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2015
Metastatic Renal Cell Carcinoma - Pipeline by Acceleron Pharma, Inc., H2 2015
Metastatic Renal Cell Carcinoma - Pipeline by Amgen Inc., H2 2015
Metastatic Renal Cell Carcinoma - Pipeline by Angiogene Pharmaceuticals Limited, H2 2015
Metastatic Renal Cell Carcinoma - Pipeline by Argos Therapeutics, Inc., H2 2015
Metastatic Renal Cell Carcinoma - Pipeline by Astellas Pharma Inc., H2 2015
Metastatic Renal Cell Carcinoma - Pipeline by Bayer AG, H2 2015
Metastatic Renal Cell Carcinoma - Pipeline by Beta Pharma, Inc., H2 2015
Metastatic Renal Cell Carcinoma - Pipeline by Bionomics Limited, H2 2015
Metastatic Renal Cell Carcinoma - Pipeline by Cellceutix Corporation, H2 2015
Metastatic Renal Cell Carcinoma - Pipeline by Celldex Therapeutics, Inc., H2 2015
Metastatic Renal Cell Carcinoma - Pipeline by Cerulean Pharma, Inc., H2 2015
Metastatic Renal Cell Carcinoma - Pipeline by Dr. Reddy's Laboratories Limited, H2 2015
Metastatic Renal Cell Carcinoma - Pipeline by EirGenix Inc., H2 2015
Metastatic Renal Cell Carcinoma - Pipeline by Eisai Co., Ltd., H2 2015
Metastatic Renal Cell Carcinoma - Pipeline by Eli Lilly and Company, H2 2015
Metastatic Renal Cell Carcinoma - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015
Metastatic Renal Cell Carcinoma - Pipeline by Exelixis, Inc., H2 2015
Metastatic Renal Cell Carcinoma - Pipeline by Genor BioPharma Co., Ltd., H2 2015
Metastatic Renal Cell Carcinoma - Pipeline by GlaxoSmithKline Plc, H2 2015
Metastatic Renal Cell Carcinoma - Pipeline by Hetero Drugs Limited, H2 2015
Metastatic Renal Cell Carcinoma - Pipeline by Hospira, Inc., H2 2015
Metastatic Renal Cell Carcinoma - Pipeline by immatics biotechnologies GmbH, H2 2015
Metastatic Renal Cell Carcinoma - Pipeline by Immune Design Corp., H2 2015
Metastatic Renal Cell Carcinoma - Pipeline by Immunicum AB, H2 2015
Metastatic Renal Cell Carcinoma - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2015
Metastatic Renal Cell Carcinoma - Pipeline by Mabion SA, H2 2015
Metastatic Renal Cell Carcinoma - Pipeline by Merck & Co., Inc., H2 2015
Metastatic Renal Cell Carcinoma - Pipeline by NewLink Genetics Corporation, H2 2015
Metastatic Renal Cell Carcinoma - Pipeline by Novartis AG, H2 2015
Metastatic Renal Cell Carcinoma - Pipeline by Oncobiologics, Inc., H2 2015
Metastatic Renal Cell Carcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015
Metastatic Renal Cell Carcinoma - Pipeline by Panacea Biotec Limited, H2 2015
Metastatic Renal Cell Carcinoma - Pipeline by Peloton Therapeutics, Inc., H2 2015
Metastatic Renal Cell Carcinoma - Pipeline by Prima BioMed Ltd., H2 2015
Metastatic Renal Cell Carcinoma - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2015
Metastatic Renal Cell Carcinoma - Pipeline by Seattle Genetics, Inc., H2 2015
Metastatic Renal Cell Carcinoma - Pipeline by Syndax Pharmaceuticals, Inc., H2 2015
Metastatic Renal Cell Carcinoma - Pipeline by TVAX Biomedical, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Metastatic Renal Cell Carcinoma Therapeutics - Recent Pipeline Updates, H2 2015
Metastatic Renal Cell Carcinoma - Dormant Projects, H2 2015
Metastatic Renal Cell Carcinoma - Dormant Projects (Contd..1), H2 2015
Metastatic Renal Cell Carcinoma - Dormant Projects (Contd..3), H2 2015
Metastatic Renal Cell Carcinoma - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Metastatic Renal Cell Carcinoma, H2 2015
Number of Products under Development for Metastatic Renal Cell Carcinoma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report